Achieve Life Sciences Announces Leadership Promotion
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pioneering company in the late-stage pharmaceutical sector, is excited to announce that Jaime Xinos has been promoted to Chief Commercial Officer. This strategic move aims to enhance the company's commercial readiness for the launch of its groundbreaking product, cytisinicline, aimed at combating nicotine addiction.
The Journey of Jaime Xinos
Joining Achieve Life Sciences in 2017 as the Executive Vice President of Commercial, Ms. Xinos has made significant contributions during her tenure. In her new capacity, she will not only oversee the day-to-day commercial operations but also spearhead the strategic preparations for the anticipated U.S. launch of cytisinicline. Key to her role will be the engagement with vital stakeholders, including patients, healthcare professionals, and payors. This coordinated effort is crucial for ensuring a successful product introduction following FDA approval.
CEO's Vision
Rick Stewart, CEO of Achieve Life Sciences, expressed his enthusiasm for Xinos’ promotion, emphasizing her leadership in the commercial sector. He stated that her innovative, patient-centered strategies will be pivotal as they get ready to introduce cytisinicline to the market. The company is dedicated to providing new hope to millions battling nicotine addictions who are in search of effective solutions.
Strategic Partnerships and Collaborations
Under Ms. Xinos’ guidance, Achieve plans to establish strategic partnerships with experienced commercialization experts. With a focus on small biotech challenges, the goal is to develop efficient, value-driven solutions that will aid in successful market entry for cytisinicline. Her extensive experience in building collaborations will play a significant role in this aspect.
Commitment to Public Health
Reflecting on her new position, Ms. Xinos stated, "I am honored to take on this significant role during such an important time for Achieve Life Sciences. Cytisinicline represents a remarkable opportunity to become the first new FDA-approved treatment for nicotine dependence in almost two decades. My priority will be establishing strong partnerships and implementing innovative strategies that enhance patient care and drive value for our stakeholders."
Experience and Expertise
With nearly 25 years of experience in the biotechnology and pharmaceutical sectors, Ms. Xinos has held various significant roles at major companies like OncoGenex, Pfizer, Novartis, and Abbott Laboratories. Recognized as a thought leader, she excels at turning scientific discoveries into commercial opportunities. She holds both a Bachelor of Arts and an MBA from the University of Illinois, adding strong academic credentials to her wealth of practical knowledge.
Addressing a Global Epidemic
Achieve Life Sciences is committed to tackling the global nicotine addiction issue, which affects around 29 million adults in the U.S. alone. Tobacco use remains the leading cause of preventable deaths, contributing to over eight million fatalities worldwide each year. With a staggering percentage of lung cancer deaths and cardiovascular-related deaths linked to smoking and secondhand smoke, the need for effective treatments is pressing.
Moreover, the rise of vaping among over 11 million adults and the increasing use among adolescents (approximately 1.6 million reported e-cigarette users in high school and middle school) highlight the urgent demand for effective cessation aids. Current offerings have not yet included FDA-approved treatments specifically designed for e-cigarette cessation.
Innovative Approach with Cytisinicline
Cytisinicline is derived from natural plant sources and holds promise due to its strong binding affinity to nicotine receptors in the brain. This investigational drug aims to help individuals reduce cravings and manage withdrawal symptoms effectively. Although still awaiting FDA approval, cytisinicline could significantly change the landscape of nicotine dependence treatment.
Frequently Asked Questions
What is Achieve Life Sciences focused on?
The company is dedicated to developing and commercializing cytisinicline for nicotine addiction treatment.
Who has been promoted at Achieve Life Sciences?
Jaime Xinos has been promoted to Chief Commercial Officer.
What role will Jaime Xinos play at Achieve Life Sciences?
She will oversee all commercial operations and prepare for the launch of cytisinicline.
How does cytisinicline work?
Cytisinicline aims to reduce cravings and withdrawal symptoms by interacting with nicotine receptors in the brain.
What is the significance of this promotion?
This role is crucial as Achieve prepares for a successful market entry for cytisinicline after FDA approval.
